British Prime Minister Boris Johnson said the coronavirus vaccine had removed a “significant hurdle” but warned that there was more to overcome before it was released widely.And on Monday, November 9, 2020, a breakthrough was announced in the global race to develop a successful vaccine against the Coronavirus COVID-19, as Pfizer and BioNTech announced that the vaccine was 90% effective in preventing people from contracting the virus during the third phase of trials.
And in September, published a draft list showing who would have been at the top of the waiting list when a coronavirus vaccine was approved in the UK.
The UK Government’s Joint Committee on Immunization and Immunization says it recommends a “simple age-based program” to decide about who gets priority.
They said this approach “will probably lead to faster delivery and better absorption of those at higher risk,”.
Here is a tentative list of their priorities:
Elderly people living in nursing homes and workers in care homes
All of those 80 years and older are health and social care workers
All those 75 years of age and over
All of those aged 70 and over
All those 65 and over
High-risk adults under the age of 65
Medium-risk adults under age 65
These are 60 years and over
All of those 55 and over
All those 50 years of age and over
Remaining population (priority to be determined later)
The committee added: “Whether priority should be given to health and social care workers above, alongside or without people most at risk of contracting COVID-19 will depend on the characteristics of vaccines when they become available and disease epidemiology at the time of delivery.”
40 potential vaccines
There are nearly 40 potential vaccines being tested globally and over 140 others in the early stages of testing, according to the World Health Organization.
However, experts told Sky News, only one in 10 of the world’s population would be protected against COVID-19 in the first year of the vaccine being available.
An analysis of global manufacturing capacity shows that only 2 billion doses could be taken in 2021, even if given the green light.
And Russia claimed to be the front runner, having already developed what the nation says is an effective vaccine – despite skipping the usual testing rounds. Eight others are in the third phase of testing, before the last step for licensing.
Besides Pfizer, one of the first contestants in this category was the stab developed by the University of Oxford and AstraZeneca, who was the first to reach this critical stage.
The US pharmaceutical giant Moderna is also making excellent progress and could have a vaccine ready soon. And US biotechnology company Novavax announced in September that it had begun the third phase of trials in the United Kingdom.
Meanwhile, countries in the northern hemisphere are facing difficulties getting influenza vaccines, according to the World Health Organization.
There is a growing demand for a flu vaccine this year amid the global coronavirus pandemic, as people scramble to protect themselves before winter. The World Health Organization did not disclose which countries are struggling to get vaccines.